BDX Stock Forecast & Price Target

Becton Dickinson has demonstrated solid financial performance, with its Medical segment (MMS) achieving sales of $888 million in FQ3'25, reflecting a year-over-year growth rate of 5.3%, driven primarily by strong demand in Infusion Systems and Pharmacy Automation. The MedTech business has consistently grown more than 6% annually since the initiation of the BD 2025 strategy, accompanied by improving margins, indicating robust operational efficiency and market positioning. Additionally, the MDS segment reported FY24 sales of $4.43 billion, a 3.2% increase year-over-year, indicating resilience and growth potential amidst varying market demands.

Becton Dickinson has reaffirmed its organic revenue growth outlook at 3.0-3.5% y/y, a reduction from the previously projected 4.0-4.5%, indicating potential stagnation in growth. In the third fiscal quarter of 2025, the company reported a revenue decline of 1.1% year-over-year, heavily influenced by decreases in key segments, including low-single digit declines in both Biosciences and Diagnostic Solutions. Additionally, the company faces significant challenges from volume-based procurement headwinds in China, coupled with reduced demand in the Biosciences sector due to government cuts and slower market recovery, further exacerbating its negative outlook.